- Policy
- Boryung's Akave will be newly listed
- by Kim, Jung-Ju Jun 26, 2020 06:42am
- Boryung's Akave 30/10mg will be newly listed next month. This drug is a combination of Fimasartan and Atorvastatin. Guerbet Korea's 14 listed pharmaceutical products, such as Lipiodol ultra liquid (Iodized oil), have a lower price. The MOHW confirmed and revised the list of drug benefits and the upper limit. It will take effect from July 1st.
- Policy
- Hanmi's Cossac was voluntarily withdrawn
- by Lee, Tak-Sun Jun 26, 2020 06:23am
- Cossac, which was once a representative medicine of sinus cold, disappeared. It was predicted when Hanmi switched marketing to 'Cossac-L', an upgraded item when it switched to Pseudoephedrine combination drug. However, since products converted to precription drugs at that time did not recover sales during OTC, it is understood that the re-
- Policy
- Penalty on 14 drug companies failed to report serialization
- by Lee, Hye-Kyung Jun 26, 2020 06:20am
- 14 pharmaceutical manufacturers and importers are facing administrative actions for neglecting serialization reporting mandate. Penalties on the nine out of 23 companies announced initially were dropped as the authority accepted their appeals. According to the ‘2019 Semi-annual Report on Manufacturer and Importer Subject to Administrati
- Policy
- The goal is to develop a corona vaccine in next year
- by Lee, Jeong-Hwan Jun 26, 2020 06:20am
- The Ministry of Health and Welfare said it was supporting a domestic COVID-19 vaccine with the goal of developing in the second half of next year and in 2022. Corona vaccines such as MERS and SARS were not developed because of the low global demand for vaccines. On the 24th, the MOHW replied to the written question of Nam In-soon, Democra
- Company
- New products join the already competitive bowel prep market
- by Lee, in-bok Jun 26, 2020 06:19am
- The bowel preparation market valued at 50 billion won is fluctuating noticeably. New products flooding in just a few years time have overly crowded the market. These products are jumping into the market with improved drug compliance for examinees and patients, but the market has not been easy for them to survive. Three types of bowel
- Company
- Pharmacist's No. 1 product among athlete's foot tx, Tiersil
- by Lee, Seok-Jun Jun 25, 2020 07:02am
- The pharmacist's recommendation for 'once-form athlete's foot treatment' was found to be due to patient convenience (40.4%), medication compliance, and therapeutic effect (39.9%). The pharmacist's No. 1 product among athlete's foot fungus drugs was investigated as 'Tiersil Once (Terbinafine Hydrochloride)’. Dailypharm conducted an online su
- Policy
- COVID-19 global clinical growth rate is about 17 times
- by Kim, Jung-Ju Jun 25, 2020 06:31am
- The global clinical trial of 'COVID-19' is steadily increasing. The increase rate is close to 17 times from March to the present. 15 cases have been approved in Korea, and research is actively underway, and as a whole, clinical trials of plasma devices using plasma of cured patients have surged 36 times. According to the trend of domestic and
- Company
- Hanmi Science Presents 6 Great Visions for Post COVID-19
- by dailypharm Jun 25, 2020 06:09am
- Hanmi Science with the gene of 'Innovation' presented six great visions for the post COVID-19. Hanmi Science's 6 visions, abbreviated as 'Cydio Cigma', imply key words as 'Cyber Education','Digital Bio','Oral Bio','City Bio','Green Bio', and 'Marine Bio'. For the vision business, CEO Chong-Yoon Lim promised to raise outstanding employees’ an
- Company
- Sanofi to dismiss 3 sales reps breaching compliance
- by An, Kyung-Jin Jun 25, 2020 06:08am
- Accused of false reporting client visits, three sales reps from Sanofi-Aventis Korea may be dismissed as recommended by the headquarters. The sales department seems to be stirred by the management and commented, “The management has made a harsh decision disregarding the possibility of system error.” The sign of internal dispute is appa
- Company
- Hanmi's Gugu was released in Japan
- by Chon, Seung-Hyun Jun 25, 2020 06:08am
- Hanmi's erectile dysfunction treatment 'Gugu' was released in Japan as a treatment for prostate hyperplasia. According to Hanmi on the 23rd, Sandoz began to sell Gugu 2.5mg and 5mg from all over Japan on the 18th. The Japanese product name is “Sandoz Tadalafil” (Tadalafil Tablets 2.5mg&8729;5mg ZA SANDOZ). Gugu is generic for Cialis,
